{"id":280639,"date":"2026-06-24T12:07:00","date_gmt":"2026-06-24T16:07:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/06\/24\/ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-use\/"},"modified":"2026-06-24T12:30:15","modified_gmt":"2026-06-24T16:30:15","slug":"ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-use","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/06\/24\/ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-use\/","title":{"rendered":"ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use"},"content":{"rendered":"<p><a href=\"https:\/\/www.pharmacytimes.com\/view\/ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-use\">ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use<\/a><\/p>\n<p><a href=\"https:\/\/www.pharmacytimes.com\/view\/ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-use\">https:\/\/www.pharmacytimes.com\/view\/ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-use<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-06-24 12:07:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.pharmacytimes.com\">www.pharmacytimes.com<\/a><\/p>\n<p class=\"\">The technology presentations at the 86th American Diabetes Association (ADA) Scientific Sessions highlighted a major shift in diabetes care. Continuous glucose monitoring (CGM) is moving beyond intensive insulin management and becoming a broader therapeutic tool for people with type 2 diabetes (T2D), while automated insulin delivery systems continue to expand and emerging ketone monitoring technologies promise to improve safety and reduce the risk of diabetic ketoacidosis (DKA). <\/p>\n<p class=\"\">For pharmacists, the message from ADA 2026 was clear: diabetes technology is no longer reserved for a small subset of highly engaged patients. Technology is increasingly being integrated throughout the continuum of diabetes care and is becoming an essential component of cardiometabolic management.<\/p>\n<h2 class=\"pb-4 pt-2 text-2xl\"><strong>CGM Expansion Beyond Insulin Therapy<\/strong><\/h2>\n<p class=\"\">One of the most important technology presentations at ADA 2026 was the randomized controlled trial, CONNECT, which evaluated the Dexcom G7 CGM system in adults with T2D not treated with insulin.1<\/p>\n<p class=\"\">CONNECT enrolled 283 adults across 22 primary care practices and provided the first Level A evidence supporting CGM use in people with T2D not using insulin. Participants randomized to CGM achieved a mean A1C reduction of 1.6% compared with 0.7% in the routine care group, representing a between-group difference of 0.9%. Additionally, 68% of CGM users achieved an A1C below 7.5%, while 46% achieved an A1C below 7.0%. Improvements were particularly impressive among participants with baseline A1C values greater than 10%, where mean A1C reduction reached 3.1%.1<\/p>\n<p class=\"\">Beyond A1C, CGM users experienced substantial improvements in time in range (70-180 mg\/dL), averaging approximately 62% versus 41% in the routine care group, equivalent to approximately 5 additional hours per day spent within target glucose range. Improvements emerged within the first month and were sustained throughout the 26-week study period.1<\/p>\n<p class=\"\">Importantly, glycemic benefits were observed regardless of concomitant&#8230;<\/p>\n<p><a href=\"https:\/\/www.pharmacytimes.com\/view\/ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-use\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use https:\/\/www.pharmacytimes.com\/view\/ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-use Publish Date: 2026-06-24 12:07:00&#8230;<\/p>\n","protected":false},"author":1,"featured_media":280640,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/cdn.sanity.io\/images\/0vv8moc6\/pharmacytimes\/bd8ad43bc71eb16decc78235bac8917cfa488c1d-7008x4672.jpg","fifu_image_alt":"","footnotes":""},"categories":[8],"tags":[66],"class_list":["post-280639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology","tag-emerging"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/280639"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=280639"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/280639\/revisions"}],"predecessor-version":[{"id":280641,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/280639\/revisions\/280641"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/280640"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=280639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=280639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=280639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}